Systemic isotretinoin in the management of acne – a patient questionnaire survey by Burger, S et al.
Original Research: Systemic isotretinoin in the management of acne – a patient questionnaire survey
427 Vol 51 No 5SA Fam Pract 2009
Abstract  SA Fam Pract 2009;51(5):427-433
Background: The primary aim was to investigate the appropriateness (as outlined in the South African Acne Treatment Guideline1) for the prescription 
of systemic isotretinoin in the management and counselling of acne in the Nelson Mandela Bay Metropole.
Methods: A questionnaire was distributed to patients receiving systemic isotretinoin by 30 community pharmacies. The response rate was 29.2% 
(57 respondents).
Results: The acne medication history revealed that commercial brands of beauty products were used by 57.9% of respondents, topical benzoyl 
peroxide by 22.8%, and systemic cotrimoxazole by 19.3%. Only nine females used an oral contraceptive as acne treatment prior to isotretinoin. The 
average daily dose of isotretinoin was 44.2 (SD=16.9) mg. Half of the respondents received a suboptimal cumulative dosage of isotretinoin. The 
average prescribed duration of isotretinoin therapy was 6.2 months. Adequate counselling was received by only 57.9% of patients. A third of the 
patients who were able to fall pregnant received recommendations for contraception. Pregnancy tests were conducted in only two females. Just over 
40% of patients reported a complete clearance of acne lesions.
Conclusions: Many prescribers did not follow the recommendations for isotretinoin prescription. The counselling of patients regarding isotretinoin 
therapy was substandard, especially with respect to pregnancy prevention.
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Introduction
Acne can be defined as a multifactorial, chronic,2 common disorder of the 
pilosebaceous unit.3 The reported incidence of acne among adolescents 
in Western societies is 79% to 95%,4 although various forms of this 
disease can affect people of all ages.5 Acne has shown to have negative 
effects on the social functioning and emotions of patients, and can be 
associated with anxiety, depression and even unemployment.1,6
The scientific understanding of the pathogenesis of acne has increased 
over the past three decades.7 There has been a shift in the clinical 
focus of acne treatment away from the resolution of advanced lesions 
towards the inhibition of the multiple pathogenic processes underlying 
the earliest acne stages.7
In South Africa, the most recent Acne Treatment Guideline was published 
in 2005.1 It was based on a consensus document of the Global Alliance 
to Improve Outcomes in Acne (GAIOA). The GAIOA was created in 2001 
as a worldwide effort to assemble a group of experts in the field of acne 
treatment. After thorough research and meetings, this group prepared 
a set of recommendations for acne management to be distributed 
to all countries taking part where the general implementation of 
these guidelines was to be encouraged. The recommendations and 
information derived from these meetings were discussed with South 
African dermatologists, where their contributions were incorporated 
into the guidelines to make them applicable specifically to South Africa. 
The recommendations are therefore representative of the current 
universal approach to acne treatment while also reflecting the thoughts 
of South African dermatologists.1
According to the GAIOA,1 four grades of acne severity (which were used 
in this study) should be considered when diagnosing and treating acne 
patients. These four stages, together with the recommended management 
of each stage according to the GAIOA,1 are shown in Table I.
Systemic isotretinoin seldom fails to clear acne and it presents a 
permanent cure for many patients. The cure rates for patients treated 
with systemic isotretinoin vary from 38 to 66%, depending on the 
definition of a cure. Overall, systemic isotretinoin is known to be the 
most effective agent in the treatment of acne.1
Even though effective, systemic isotretinoin can cause a wide range of 
side-effects. Some of these side-effects are serious, but most of them 
are more unpleasant than serious.1 The more dangerous side-effects 
(for example teratogenicity and the possibility of negative psychological 
impact) have triggered a continual debate among the medical society 
and general public worldwide regarding the prescription and use of 
isotretinoin.8 Systemic isotretinoin is the drug of choice for severe acne, 
but the popularity of the prescription of isotretinoin for less severe cases, 
where other more conservative treatments may have been successful, 
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has increased. Prescribers should adhere to the recommended 
indications for the use of this agent.1 According to the GAIOA, systemic 




- three months of combination treatment including systemic 
tetracyclines, and/or




systemic antibiotics are needed.
The South African Acne Treatment Guideline (SAATG)1 is available to aid 
South African health care professionals in prescribing acne medication 
optimally, in providing necessary counselling, in conducting required 
monitoring procedures and in the overall care of acne patients, especially 
pertaining to isotretinoin. The extent to which this guideline (and 
additional recommendations regarding acne treatment derived from the 
literature) is followed by health care professionals is questionable.
Aim and objectives
The primary aim of this study was to investigate the appropriateness 
(as optimally outlined in the SAATG)1 of the prescription of systemic 
isotretinoin in the management of acne in the Nelson Mandela Bay 
Metropole (NMBM) in South Africa, and to investigate the accompanying 
counselling and monitoring of systemic isotretinoin patients. The more 








prior to and during therapy with isotretinoin
•	 The	appropriateness	and	presence	of	patient-monitoring	procedures	
prior to and during isotretinoin therapy
•	 Presence	 and	 severity	 of	 side-effects	 experienced	 by	 patients	 on	
isotretinoin therapy, and
•	 Patients’	perceived	satisfaction	regarding	the	outcomes	of	isotretinoin	
treatment and the tolerability of side-effects experienced during 
treatment
Methodology
After a thorough literature review, a structured questionnaire consisting 
of open and closed questions was designed. The questionnaire was 
designed specifically for patients who were on systemic isotretinoin 
therapy during the time of the study. The sections in the questionnaire 
included demographic information, patient history of acne and acne 
treatment, patient history of co-morbid conditions and other medications, 
details on systemic isotretinoin therapy, details on patient counselling and 
monitoring, side-effects experienced by patients while on isotretinoin, 
perceived patient satisfaction or dissatisfaction with isotretinoin and 
a section specifically regarding pregnancy prevention for females on 
isotretinoin.
A pilot study was conducted by distributing questionnaires to two 
pharmacies in the NMBM by means of convenience sampling. The 
pharmacists were asked to distribute the questionnaires to patients 
who were currently receiving isotretinoin from the pharmacy. Only minor 
changes to the questionnaire were required after the pilot study.
A list of all community pharmacies in the NMBM in 2006 was obtained 
from the South African Pharmacy Council. There were 89 pharmacies 
on the list, of which one-third (30 pharmacies) were selected for the 
study by means of a stratified randomised sampling method. Individual 
discussions were held with each of the responsible pharmacists of the 
selected pharmacies in order to obtain permission for the inclusion of their 
pharmacies and their patients using isotretinoin in the study. Envelopes, 
each containing a patient information letter, a questionnaire, an ethical 
consent form and an ethical assent form, were personally delivered to 
each pharmacy. The information letter was directed to the participant, or 
the parent or guardian of the participant. It served to inform the patient 
of the voluntary and anonymous nature of participation, as well as to 
explain the correct procedure of completing both the questionnaire and 
the ethical forms. It was requested that isotretinoin patients younger 
than 18 years of age only complete the form under the guidance of a 
parent, guardian or pharmacist. The consent forms were to be signed 
by all respondents aged 21 years or older, or by parents or guardians 
of respondents younger than 21 years of age. The assent forms were 
to be signed by respondents younger than 21 years of age in order to 
give permission to their parents or guardians to sign the consent forms 
Table I: Grading of acne severity according to the GAIOA1
Grade of 
acne Description of acne Management guidelines
Grade 1 Comedones only Topical management. A topical retinoid 
will suffice in most cases, but addition of 
benzoyl peroxide or azelaic acid may be 
necessary in resistant cases.
Grade 2 Inflammatory papules 
present in addition to 
comedones
In milder cases with superficial 
inflammatory papules: the same treatment 
as for Grade 1 acne. Where papules are 
more deeply situated, systemic antibiotics 
are indicated.
Grade 3 Pustules present in 
addition to any of the 
above
Systemic antibiotics are necessary. These 
should always be used in combination 
with a topical retinoid and, if the systemic 
treatment needs to go on for longer than 
three months, a topical anti-resistance 
agent should be added.
Hormonal treatment can be used in female 
patients who desire contraception or who 
have other gynaecological indications for 
this treatment.
Grade 4 Nodules, cysts, 
conglobate lesions 
or ulcers present in 
addition to any of the 
above
Systemic isotretinoin is the drug of choice.
Oral contraceptives combined with anti-
androgens can sometimes be effective in 
females.
Systemic antibiotics can bring about 
excellent improvement, but the 
improvement is of short duration and 
systemic antibiotics do not represent a 
long-term solution for this type of acne and 
unacceptably long antibiotic courses are 
usually necessary.
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on	their	behalves.	The	Nelson	Mandela	Metropolitan	University’s	Human	
Ethics Committee granted ethical approval for the study.
Pharmacists were asked to hand an envelope to every patient who was 
receiving isotretinoin from the pharmacy when they came to the pharmacy 
for medication. Pharmacists were also asked to explain the procedure of 
completing the questionnaire and ethical forms to the patient, as well 
as to emphasise the importance of the study and the return date of the 
questionnaire and ethical forms. Patients had to complete the forms and 
return them to their pharmacies. The total time for data collection was 
12 weeks. In this time, each pharmacy received three telephone calls as 
reminders of the study. Altogether, 189 questionnaires were distributed.
The questionnaires were retrospectively analysed using quantitative 
techniques. Microsoft Office Excel® 2003 was used for the basic 
differential analysis of the data. Numeric analysis comprised of the 
mean values, standard deviations, the range of data and minimum and 
maximum values that were calculated. Inferential tests were employed 
in order to obtain statistical and practical significance of the results. In 
obtaining	 statistical	 significance	 based	 on	 frequencies,	 the	 Pearson’s	
chi-square test was used, while the t-test was used to obtain statistical 
significance where two groups based on sample means were compared. 
The	Cramér’s	V	statistic	was	used	to	confirm	practical	significance	of	the	
chi-square	test,	and	the	Cohen’s	d	statistic	was	employed	to	confirm	the	
practical significance of the t-test.
Limitations of the study were that it only included pharmacies and 
patients in the NMBM and that a relatively small number of patients 
were included in the study.
Results
Demographic information
A total of 57 completed questionnaires were received, accounting for a 
response rate of 29.2%. Of the 57 patients, 24 (42.1%) were female and 
33 were male (57.9%). The age distribution of the patients is outlined 
in Table II. The average age of the population was 20.2 years (standard 
deviation (SD) = 7.9 years; n = 57). The average age that acne started 
to develop in the population was 15.3 years (SD = 4.4 years; n = 56). 
The youngest age of acne development was eight years, while the 
highest age was 38 years.
Acne medication history
The acne medication history represented medications, or any other 
treatment method, used by patients prior to the initiation of systemic 
isotretinoin therapy. Commercial brands of beauty products in cream, 
gel and face wash formulations were used by 33 patients (57.9%). 
Topical benzoyl peroxide formulations were used by 13 patients (22.8%), 
while 11 patients (19.3%) used systemic cotrimoxazole. A tetracycline 
derivative (minocycline, doxycycline or lymecycline) was used by 12 
patients (21.1%). Only nine females (37.5%; n = 24) stated to have used 
an oral contraceptive as acne treatment prior to isotretinoin therapy.
Systemic isotretinoin therapy
The most frequently prescribed isotretinoin dose was 40 mg daily, 
prescribed to 42.1% of the patients (n = 38). The average daily dose 
was 44.2 mg (SD = 16.9 mg; n = 38). The average prescribed duration 
of isotretinoin therapy was 6.2 months (SD = 3.4 months; n = 50). 
The optimal cumulative dosage for isotretinoin is 120 to 150 mg/kg.1 
Only 34 patients completed all areas of the questionnaire necessary for 
determining the cumulative isotretinoin dose (dose per day, duration 
of therapy and weight). It was determined that seven (20.6%) of these 
patients would have received a cumulative dose within the optimal 
range, while 10 patients (29.4%) would have received a cumulative dose 
higher than 150 mg/kg. The other 17 patients (50.0%) would all have 
received a suboptimal cumulative dosage.
Acne severity
Before isotretinoin therapy, 29 patients (50.9%) had acne on areas of the 
body other than the face; the most frequently affected body area being 
the torso. Isotretinoin was prescribed to 3 patients (5.3%) with Grade 1 
acne, 17 patients (29.8%) with Grade 2 acne, 21 patients (36.8%) with 
Grade 3 acne and 16 patients (28.1%) with Grade 4 acne.
Counselling and monitoring procedures
Health care professionals included dermatologists, general practitioners 
and pharmacists. Dermatologists prescribed isotretinoin to 45 patients 
(78.9%), while 11 patients (19.3%) received prescriptions from general 
practitioners. One patient (a pharmacist) self-initiated isotretinoin therapy. 
Only 33 patients (57.9%) were counselled adequately regarding their 
isotretinoin therapy course, while 24 patients (42.1%) received partial 
information, were not requested to sign a consent form or did not receive 
(or could not remember receiving) any counselling from the prescriber at 
all. Eight patients (72.7%; n = 11) who received isotretinoin prescriptions 
from general practitioners and 15 patients (33.3%; n = 45) who received 
prescriptions from dermatologists did not receive adequate counselling. 
Pharmacists counselled 78.2% of patients sufficiently. Although more 
patients claimed to have been counselled by their pharmacists than 
by their prescribers, there was a higher percentage of counselling by 
the prescriber reported for individual counselling topics. Three females 
(12.5%; n = 24) did not receive any counselling regarding the danger 
of isotretinoin in pregnancy. The ages of these females were 22 years, 
16 years and 17 years – all three of childbearing age. Thirteen patients 
(22.8%) were not weighed prior to isotretinoin therapy prescription. 
Cholesterol tests were conducted for 36 patients (63.2%) and liver 
enzyme tests for 38 patients (66.7%).
Reported side-effects
The frequency of the occurrence of side-effects, as reported by the 
patient population, is outlined in Table III. Cheilitis was the most frequently 
experienced side-effect, reported by 56 patients (98.2%). Dry skin was 
reported by 50 patients (87.7%), while an initial worsening of acne (flare-
Table II: Age distribution of patient population









13–18 31 54.4 54.4
19–24 21 36.8 91.2
25–34 2 3.5 94.7
35–49 2 3.5 98.2
≥ 65 1 1.8 100.0
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up) was experienced by 36 patients (63.2%). The recommended short 
course of prednisone, which serves to alleviate this side-effect,9 was 
prescribed to only 11 of these patients (30.6%; n = 36).
Depression was reported by 24 patients (42.1%) and 8 patients (14.0%) 
experienced suicidal thoughts while on isotretinoin therapy. Also of note 
was that 17 patients (29.8%) reported sudden urges to fall asleep while 
on the medication. Fourteen patients had a decreased appetite and 
weight loss occurred in 10 patients. Contradictory to this, nine patients 
reported noticeable weight gain.
Isotretinoin and pregnancy prevention
Of the 24 female patients, 16 (66.7%) stated that they possessed 
childbearing potential. Three patients reported that they were not able 
to fall pregnant, while five females chose not to answer this question 
in the questionnaire. Fourteen females reported on their contraceptive 
measures prior to and during isotretinoin therapy. The results are shown 
in Table IV. After commencement of therapy, no changes occurred in 
the contraceptive methods utilised by patients, except for one patient 
who ceased taking her oral contraceptives and started practising 
abstinence. Only one female used two contraceptive measures. 
Contraception was recommended to only five of the sixteen females who 
were able to fall pregnant (31.3%), while not one patient between 13 
and 18 years of age received recommendations from their prescribers 
regarding contraception. Only four females (21.1%; n = 19) received 
correct information from their health care professionals regarding the 
teratogenicity of isotretinoin and the procedure that must be followed 
should pregnancy occur while on treatment. Pregnancy tests were 
conducted in two females (8.3%; n = 24).
Efficacy of isotretinoin
There	was	a	noticeable	improvement	in	the	patients’	acne	severity	since	
initiation of therapy. This was confirmed by the smaller number of patients 
who suffered grades 2, 3 and 4 acne after starting with isotretinoin when 
compared to prior to isotretinoin therapy initiation. This difference was 
significant (chi²(4) = 46.67; p < 0.0005; V = 0.64 Large). Just over 40% 
of patients reported a complete clearance of acne lesions during their 
isotretinoin therapy course. A significantly lower number of patients 
reported to have acne on the torso area, neck, shoulders, arms, scalp 
and legs after the initiation of isotretinoin (chi²(1) = 14.88; p < 0.0005; 
V = 0.55 Large). More than 80% of patients felt either very satisfied or 
satisfied with the perceived efficacy of isotretinoin. Although many side-
effects were reported, 71.9% of patients felt that their quality of life was 
not negatively affected or only affected negatively to a small degree. The 
questionnaire posed a hypothetical scenario to the patients: If they were 
able to return to the moment when isotretinoin was prescribed to them, 
would they have chosen to use isotretinoin again? Eight patients (14.0%) 
reported that they would have chosen not to use isotretinoin, while the 
other patients all stated that they would have made the same decision.
Discussion
The results of this study indicated that the recommendations for the 
prescription of isotretinoin are not always followed by prescribers. 
For example, in South Africa, the use of an effective contraceptive measure 
one month prior to, during and for one month after isotretinoin therapy 
is recommended.1 In the United States of America (USA), the use of two 
contraceptive measures is required for females on isotretinoin therapy,10 
while two complementary contraceptives are recommended in the United 
Kingdom.11 Of the 16 patients who stated that they were able to fall 
pregnant, only 5 (31.3%) received recommendations for contraception 
from their health care professionals. Even though females must be fully 
aware of the teratogenicity of isotretinoin and should sign consent forms 
indicating their understanding of the fact that a therapeutic abortion 
would be compulsory if pregnancy occurred during isotretinoin therapy,1 
only four females (21.1%; n = 19) received correct information from 
their health care professionals regarding this fact. A negative pregnancy 
test prior to initiation of isotretinoin therapy and monthly thereafter is 
Table III: Frequency of side-effects reported most by patient population*
Rank Side-effects
Patients
Number (n = 57) Percentage (%)
1 Dry lips 56 98.2
2 Dry skin 50 87.7
3 Initial acne flare-up 36 63.2
4 Dry eyes 32 56.1
5 Nose bleeding 31 54.4
6 Sunburn 30 52.6
7 Backache 25 43.9
8 Depression 24 42.1
8 Fatigue 24 42.1
9 Muscle pains 23 40.4
10 Dizziness 22 38.6
10 Headache 22 38.6
10 Slow healing wounds 22 38.6
10 Joint pains 22 38.6
11 Neck stiffness 18 31.6
12 Sudden urges to fall asleep 17 29.8
12 Constipation 17 29.8
13 Loss of appetite 14 24.6
14 Blurred vision 13 22.8
14 Hair loss 13 22.8
15 Anxiety 11 19.3
16 Ingrown nails 10 17.5
16 Weight loss 10 17.5
* Only side-effects with a frequency of 10 or more are reported in Table III.


















Oral contraceptive 6 42.9 5 35.7
Abstinence 5 35.7 6 42.9
Injectable contraceptive 1 7.1 1 7.1
Vasectomy of husband 1 7.1 1 7.1
Hysterectomy 1 7.1 1 7.1
None 1 7.1 1 7.1
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highly recommended in the SAATG1 and is compulsory in the USA,9 but 
pregnancy tests were only conducted in two females (8.3%; n = 24). 
There	was	a	significant	improvement	in	the	patients’	acne	severity	since	
initiation of therapy and just over 40% of patients reported a complete 
clearance of acne lesions during their isotretinoin therapy course.
The response rate to the questionnaire survey was low and thereby 
limited the validity of the results and of the statistical tests that could 
be performed. A nationwide survey will allow for results more accurately 
representative of the South African population. The low response rate 
could have been caused by a variety of factors, including the lack of 
personal communication with the respondents, the dependence of the 
researcher on the goodwill and responsible participation of pharmacists 
and patients, the lack of cooperation by many pharmacists, the 
complicated ethical forms that had to be completed by patients and the 
length of the questionnaire. Even though the questionnaire contained 
mainly multiple choice or open-ended questions and was designed to be 
as direct, patient-friendly and concise as possible, some patients might 
have found it time-consuming. In review of the study, it was observed 
that it would have been more appropriate to target a patient population 
who had already completed treatment courses with systemic isotretinoin, 
instead of patients who were currently on isotretinoin. The reason for this 
retrospective discovery was that patients who already completed their 
isotretinoin courses would have been able to give more consistent and 
valid feedback regarding the outcomes of therapy. Patients could have 
been at any stage of therapy during completion of the questionnaire, 
which could have affected factors like side-effects experienced, levels 
of	 acne	 clearance	 and	 patients’	 satisfaction	with	 the	 effectiveness	 of	
isotretinoin.
Conclusion and recommendations
Many prescribers did not follow the recommendations for isotretinoin 
prescription as stipulated in the SAATG.1 Isotretinoin was prescribed to 
many patients who did not have Grade 4 acne and who had not received 
previous prescriptions for systemic antibiotic therapy or hormone therapy, 
which might have been effective if tried before resorting to isotretinoin. 
However, the psychological aspects and scarring potential of the patients 
were	 not	 investigated	 and	 could	 have	 contributed	 to	 the	 prescribers’	
decisions. A majority of patients received inappropriate cumulative doses, 
which, if too low could lead to recurrent acne, or if too high could have 
led to severe (unnecessary) side-effects. The effectiveness of isotretinoin 
were proven once again, as just over 40% of patients (who were still 
on isotretinoin) reported a complete clearing of acne, while over 80% 
of patients felt satisfied or very satisfied with the perceived efficacy of 
isotretinoin. Counselling of patients regarding isotretinoin therapy was 
substandard by all health care professionals. Monitoring procedures as 
recommended in the SAATG1 were largely insufficient and not conducted 
in accordance with recommendations. Special emphasis is placed 
on the unacceptable lack of compliance of health care professionals 
in implementing pregnancy prevention measures among female 
isotretinoin users and counselling females in this regard. The reservation 
of the prescription of systemic isotretinoin to dermatologists only should 
be considered, as well as the implementation of a stringent national 
Pregnancy Prevention Programme in South Africa. The implementation 
of this programme should be compulsory for all females on isotretinoin 
therapy and all health care professionals involved in the care of females 
on isotretinoin therapy. Although guidelines for isotretinoin prescription 
are available in South Africa, a national consensus flowchart or protocol 
for the prescription of isotretinoin therapy should be designed and 
implemented. 
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